- Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma
Heike Niessner et al, 2023, Cancers CrossRef - Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
Francisco Meraz-Torres et al, 2024, Journal of Experimental & Clinical Cancer Research CrossRef - Primary Undifferentiated/Dedifferentiated Cutaneous Melanomas—A Review on Histological, Immunohistochemical, and Molecular Features with Emphasis on Prognosis and Treatment
Dana Antonia Țăpoi et al, 2023, International Journal of Molecular Sciences CrossRef - Does BRAF V600E mutation affect recurrence rate of ameloblastomas? Systematic review and meta‐analysis
Allan Vinícius Martins‐de‐Barros et al, 2023, Journal of Oral Pathology & Medicine CrossRef - Multimodal integration of image, epigenetic and clinical data to predict BRAF mutation status in melanoma
Lucas Schneider et al, 2023, European Journal of Cancer CrossRef - Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat)
Adriana Celesia et al, 2023, International Journal of Molecular Sciences CrossRef - Incidence of BRAF Mutations in Cutaneous Melanoma: Histopathological and Molecular Analysis of a Ukrainian Population
Oleksandr Dudin et al, 2023, Melanoma Management CrossRef - A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
Xiaoting Wei et al, 2024, European Journal of Cancer CrossRef - Assessment of RAS-RAF-MAPK Pathway Mutation Status in Healthy Skin, Benign Nevi, and Cutaneous Melanomas: Pilot Study Using Droplet Digital PCR
Elena-Georgiana Dobre et al, 2024, International Journal of Molecular Sciences CrossRef